Perspective Therapeutics (NASDAQ:CATX) Now Covered by Piper Sandler

Piper Sandler initiated coverage on shares of Perspective Therapeutics (NASDAQ:CATX) in a report released on Thursday morning, Marketbeat reports. The brokerage issued an overweight rating and a $16.00 price objective on the stock.

A number of other equities research analysts also recently issued reports on CATX. Wedbush restated an “outperform” rating and set a $11.00 price objective on shares of Perspective Therapeutics in a research report on Friday, January 30th. B. Riley Financial dropped their price objective on shares of Perspective Therapeutics from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday, November 18th. UBS Group reduced their target price on shares of Perspective Therapeutics from $18.00 to $7.00 and set a “buy” rating on the stock in a research note on Friday, November 21st. HC Wainwright raised their target price on shares of Perspective Therapeutics from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Friday, January 30th. Finally, Truist Financial started coverage on shares of Perspective Therapeutics in a research note on Monday, November 24th. They set a “buy” rating and a $12.00 price target for the company. Seven analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $11.86.

Perspective Therapeutics Price Performance

Shares of NASDAQ CATX traded down $0.15 during mid-day trading on Thursday, hitting $5.50. 997,091 shares of the company’s stock traded hands, compared to its average volume of 4,880,406. Perspective Therapeutics has a 1 year low of $1.60 and a 1 year high of $6.16. The business has a 50-day moving average of $3.36. The company has a market capitalization of $408.86 million, a P/E ratio of -6.11 and a beta of 1.75.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in CATX. UBS Group AG grew its stake in Perspective Therapeutics by 44.5% in the 4th quarter. UBS Group AG now owns 926,331 shares of the company’s stock worth $2,547,000 after acquiring an additional 285,188 shares in the last quarter. AXQ Capital LP raised its position in Perspective Therapeutics by 24.2% during the 4th quarter. AXQ Capital LP now owns 12,749 shares of the company’s stock valued at $35,000 after purchasing an additional 2,481 shares in the last quarter. Avidity Partners Management LP lifted its holdings in shares of Perspective Therapeutics by 7.2% in the 4th quarter. Avidity Partners Management LP now owns 3,210,733 shares of the company’s stock worth $8,830,000 after buying an additional 216,700 shares during the period. Aigen Investment Management LP bought a new position in shares of Perspective Therapeutics during the 4th quarter worth $28,000. Finally, nVerses Capital LLC bought a new position in shares of Perspective Therapeutics during the 4th quarter worth $31,000. Hedge funds and other institutional investors own 54.66% of the company’s stock.

About Perspective Therapeutics

Isoray, Inc, through its subsidiary, IsoRay Medical, Inc, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities.